NCT04216524 2026-03-04Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell NeoplasmM.D. Anderson Cancer CenterPhase 2 Recruiting40 enrolled
NCT03113643 2025-11-04SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)Dana-Farber Cancer InstitutePhase 1 Recruiting72 enrolled